1
|
Langdon K, Cosentino S, Wawryk O. Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis. Cancer Rep (Hoboken) 2024; 7:e2035. [PMID: 38507294 PMCID: PMC10953833 DOI: 10.1002/cnr2.2035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 02/17/2024] [Accepted: 02/26/2024] [Indexed: 03/22/2024] Open
Abstract
BACKGROUND Recent advances in the treatment of acute promyelocytic leukemia (APML) have seen unprecedented improvements in patient outcomes. However, such rapid growth in understanding often leads to uncertainty regarding superiority among candidate treatment regimens, especially when further scrutinized from an epidemiological perspective. AIMS The aim of this systematic review with epidemiological analysis was to identify and compare commonly utilized protocols for standard-risk APML with a particular focus on complete remission (CR), overall/disease-free survival (DFS), and reported adverse events. METHODS AND RESULTS Medline, Scopus, and CINAHL were interrogated to identify studies utilizing all-trans retinoic acid (ATRA) in addition to arsenic trioxide (ATO) and/or anthracyclines such as idarubicin (IDA) in the treatment of de-novo APML. After collation of studies, an epidemiological analysis was subsequently performed to compare protocols with regards to outcomes of interest using number needed to benefit (NNB) and number needed to harm (NNH) measures. Seventeen articles, describing 12 distinct trials, were included in the analysis. These trials made use of three unique protocols; CR rates were 94%-100% for ATO/ATRA regimens, 95%-96% for ATO/ATRA/anthracycline regimens, and 89%-94% for ATRA/anthracycline regimens. Epidemiological analysis demonstrated NNB for CR was 9.09 (ATO/ATRA vs. ATRA/IDA) and 20.00 (ATO/ATRA vs. ATO/ATRA/IDA), NNH for neutropenia was -3.45 (ATO/ATRA vs. ATRA/IDA), and NNH for infection was -3.13 (ATO/ATRA vs. ATRA/IDA) and -1.89 (ATO/ATRA vs. ATO/ATRA/IDA). CONCLUSION The ATO/ATRA regimen is superior to chemotherapy-containing protocols at inducing remission and promoting survival in patients with APML. The regimen is better tolerated than the proposed alternatives with fewer adverse events. Future research opportunities include quantifying APML epidemiology and pursuing oral arsenic as an option for simplification of therapeutic protocols.
Collapse
Affiliation(s)
- Kane Langdon
- College of Medicine and DentistryJames Cook UniversityCairnsQueenslandAustralia
- Division of MedicineCairns Base HospitalCairnsQueenslandAustralia
- Division of Medicine, Dentistry and Health SciencesUniversity of MelbourneMelbourneVictoriaAustralia
| | - Stevie Cosentino
- Division of MedicineCairns Base HospitalCairnsQueenslandAustralia
| | - Olivia Wawryk
- Division of Medicine, Dentistry and Health SciencesUniversity of MelbourneMelbourneVictoriaAustralia
| |
Collapse
|
2
|
Lee A, McCarthy D, Bergin RJ, Drosdowsky A, Martinez Gutierrez J, Kearney C, Philip S, Rafiq M, Venning B, Wawryk O, Zhang J, Emery J. Data Resource Profile: Victorian Comprehensive Cancer Centre Data Connect. Int J Epidemiol 2023; 52:e292-e300. [PMID: 37889594 PMCID: PMC10749758 DOI: 10.1093/ije/dyad148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 10/16/2023] [Indexed: 10/29/2023] Open
Affiliation(s)
- Alex Lee
- Department of General Practice, Faculty of Medicine, University of Melbourne and Centre for Cancer Research, Parkville, VIC, Australia
| | - Damien McCarthy
- Department of General Practice, Faculty of Medicine, University of Melbourne and Centre for Cancer Research, Parkville, VIC, Australia
| | - Rebecca J Bergin
- Department of General Practice, Faculty of Medicine, University of Melbourne and Centre for Cancer Research, Parkville, VIC, Australia
| | - Allison Drosdowsky
- Department of General Practice, Faculty of Medicine, University of Melbourne and Centre for Cancer Research, Parkville, VIC, Australia
| | - Javiera Martinez Gutierrez
- Department of General Practice, Faculty of Medicine, University of Melbourne and Centre for Cancer Research, Parkville, VIC, Australia
- Department of Family Medicine, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Chris Kearney
- Department of General Practice, Faculty of Medicine, University of Melbourne and Centre for Cancer Research, Parkville, VIC, Australia
| | - Sally Philip
- Department of General Practice, Faculty of Medicine, University of Melbourne and Centre for Cancer Research, Parkville, VIC, Australia
| | - Meena Rafiq
- Department of General Practice, Faculty of Medicine, University of Melbourne and Centre for Cancer Research, Parkville, VIC, Australia
- Epidemiology of Cancer and Healthcare Outcomes (ECHO) Group, UCL, London, UK
| | - Brent Venning
- Department of General Practice, Faculty of Medicine, University of Melbourne and Centre for Cancer Research, Parkville, VIC, Australia
| | - Olivia Wawryk
- Department of General Practice, Faculty of Medicine, University of Melbourne and Centre for Cancer Research, Parkville, VIC, Australia
| | - Jianrong Zhang
- Department of General Practice, Faculty of Medicine, University of Melbourne and Centre for Cancer Research, Parkville, VIC, Australia
| | - Jon Emery
- Department of General Practice, Faculty of Medicine, University of Melbourne and Centre for Cancer Research, Parkville, VIC, Australia
| |
Collapse
|
3
|
Moshegov S, Seth I, Wawryk O, Sandhu SS, Lanteri M, Baird PN, Sahebjada S. Vision-Related Quality of Life and Ocular Parameters in End-Stage Renal Disease Patients Undergoing Hemodialysis. J Curr Ophthalmol 2023; 35:66-72. [PMID: 37680282 PMCID: PMC10481989 DOI: 10.4103/joco.joco_56_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2022] [Revised: 12/01/2022] [Accepted: 12/02/2022] [Indexed: 09/09/2023] Open
Abstract
Purpose To evaluate the vision-related quality of life (VRQoL) of patients receiving hemodialysis through the assessment of the impact of vision impairment (IVI) questionnaire and ocular parameters, including best-corrected visual acuity (BCVA), intraocular pressure (IOP), and refraction as calculated by spherical equivalent (SE) of each eye. Methods Fifty-one patients with end-stage renal disease undergoing hemodialysis at a single center were recruited, and a total of 77 eyes were evaluated. BCVA, IOP, and SE were evaluated before and after hemodialysis (within 30 min). Results Of the 51 patients recruited, 13 (25%) were female, 37 (73%) were male, and one (2%) chose not to specify gender. The mean age was 61.85 ± 32 years. The mobility IVI score was correlated significantly with the presence of hypertension (P = 0.01), eye drop usage (P = 0.04), and gender (P = 0.04). Emotional IVI scores were correlated significantly with diabetes (P = 0.03) and hypertension (P < 0.01). IOP significantly correlated with the IVI overall score (P = 0.02), including the reading IVI subscale and the emotional IVI subscale. Several factors were associated with posthemodialysis ocular parameters, including predialysis ocular parameters, age, and hypertension (P < 0.05 for all). Conclusions IOP significantly correlated with VRQoL in hemodialysis patients. Demographic variables such as diabetes status, hypertension, eye drop usage, and gender also significantly correlated with subsections of the IVI questionnaire. This study investigated the relationship between ocular parameters and VRQoL in hemodialysis patients, and future longitudinal research is needed to further elucidate the mechanisms.
Collapse
Affiliation(s)
- Sophia Moshegov
- Centre for Eye Research Australia, Melbourne, Australia
- Department of Surgery, Ophthalmology, The University of Melbourne, Melbourne, Australia
| | - Ishith Seth
- Centre for Eye Research Australia, Melbourne, Australia
- Department of Surgery, Bendigo Health, Bendigo, Victoria, Australia
| | - Olivia Wawryk
- Department of General Practice, The University of Melbourne, Melbourne, Australia
| | - Sukhpal Singh Sandhu
- Centre for Eye Research Australia, Melbourne, Australia
- Department of Surgery, Ophthalmology, The University of Melbourne, Melbourne, Australia
- Royal Victorian Eye and Ear Hospital, Melbourne, Australia
| | | | - Paul N. Baird
- Department of Surgery, Ophthalmology, The University of Melbourne, Melbourne, Australia
| | - Srujana Sahebjada
- Centre for Eye Research Australia, Melbourne, Australia
- Royal Victorian Eye and Ear Hospital, Melbourne, Australia
| |
Collapse
|
4
|
Collins A, Gurren L, McLachlan SA, Wawryk O, Philip J. Communication about early palliative care: A qualitative study of oncology providers' perspectives of navigating the artful introduction to the palliative care team. Front Oncol 2022; 12:1003357. [PMID: 36568185 PMCID: PMC9780660 DOI: 10.3389/fonc.2022.1003357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Accepted: 11/04/2022] [Indexed: 12/13/2022] Open
Abstract
Background Despite robust evidence for the integration of early palliative care for patients with advanced cancer, many patients still access this approach to care late. Communication about the introduction of Early Palliative Care is an important skill of healthcare providers working in this setting. In the context of limited community understanding about palliative care, patients and their families may express fear or negative reactions to its early introduction. Health professionals may lack the confidence or skill to describe the role and benefits of early palliative care. Aim This study sought to explore clinicians' perspectives on communication about referral to early palliative care, specifically identifying facilitators in undertaking this communication task. Methods An exploratory qualitative study set within a tertiary oncology service in Victoria, Australia. Semi-structured interviews were conducted with purposively sampled oncology clinicians exploring their perspectives on communication about referral to early palliative care. A reflexive thematic analysis was undertaken by two researchers, including both latent and semantic coding relevant to the research question. Reporting of the research was guided by the Consolidated Criteria for Reporting Qualitative Research (COREQ) checklist. Results Twelve oncology clinicians (58% female, with 67% > 15 years clinical experience) from medical oncology, surgical oncology, and haematology participated. The artful navigation of communication about early palliative care was characterised by the need for a 'spiel' involving the adoption of a series of strategies or 'tactics' when introducing this service. These themes included: 1) Using carefully selected and rehearsed language; 2) Framing in terms of symptom control; 3) Framing as additive to patient care; 4) Selling the service benefits of early palliative care; 5) Framing acceptance of referral as an altruistic act; and 6) Adopting a phased approach to delivering information about palliative care. Implications This study highlights the wide ranging and innovative communication strategies and skills required by health professionals to facilitate referral to early palliative care for cancer patients and their families. Future focus on upskilling clinicians around communication of this topic will be important to ensure successful implementation of models of early palliative care in routine cancer care.
Collapse
Affiliation(s)
- Anna Collins
- Department of Medicine, St. Vincent’s Hospital, University of Melbourne, Melbourne, VIC, Australia,*Correspondence: Anna Collins,
| | - Lorna Gurren
- Department of Medicine, St. Vincent’s Hospital, University of Melbourne, Melbourne, VIC, Australia
| | - Sue-Anne McLachlan
- Department of Medical Oncology, St. Vincent’s Hospital, University of Melbourne, Melbourne, VIC, Australia
| | - Olivia Wawryk
- Department of Medicine, St. Vincent’s Hospital, University of Melbourne, Melbourne, VIC, Australia
| | - Jennifer Philip
- Department of Medicine, St. Vincent’s Hospital, University of Melbourne, Melbourne, VIC, Australia,Parkville Integrated Palliative Care Service, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
| |
Collapse
|
5
|
Wong AK, Philip J, Wawryk O, Sabe MG, Yoong J, Everitt R, Mendis R, Chua J, Pisasale M, Le B. A Multi-Centre COVID-19 Study Examining Symptoms and Medication Use in the Final Week of Life. J Pain Symptom Manage 2022; 64:e139-e147. [PMID: 35644508 PMCID: PMC9134756 DOI: 10.1016/j.jpainsymman.2022.05.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 05/06/2022] [Accepted: 05/07/2022] [Indexed: 11/23/2022]
Abstract
CONTEXT Guidelines exist to direct end-of-life symptom management in COVID-19 patients. However, the real-world symptom patterns, and degree of concordance with guidelines on medication use, and palliative care involvement has received limited attention. OBJECTIVES To describe the evolution of COVID-19 symptoms, medication used to alleviate these, and degree of palliative care involvement in the final week of life. METHODS This retrospective study reviewed all COVID-19 inpatient deaths across five metropolitan hospitals in Australia from January 1 to December 31, 2020. Outcome measures were collected at day of death, and days one, two, five and seven before death. These were COVID-19 symptom severity (measured by the Palliative Care Outcome Scale), and use of supportive pharmacological and non-pharmacological therapies. Palliative care referral timepoint was also collected. RESULTS Within the sample of 230 patients, commonest symptoms were breathlessness, agitation, pain, and respiratory secretions. On day of death, 79% (n = 181) experienced at least one symptom, and 30% (n = 68) experienced severe/extreme symptoms. The use of midazolam, glycopyrrolate, and infusions for symptom management occurred late, less frequently, and at lower doses than suggested in guidelines and other studies. Palliative care referrals were made late, at median three days before death (IQR 1-6 days), and for only half of people dying from COVID-19 (51%; n = 118). CONCLUSION Symptoms peaked in final three days of life. Earlier use of in fusional and breakthrough medications should be considered in anticipation of symptoms given high likelihood of dying in discomfort. Earlier palliative care referral for high-risk patients should be considered at hospital admission.
Collapse
Affiliation(s)
- Aaron K Wong
- Parkville Integrated Palliative Care Service (A.K.W., J.P., R.E., J.C., B.L.) Peter MacCallum Cancer Centre & The Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Medicine (A.K.W., J.P., O.W.), University of Melbourne, Fitzroy, Victoria, Australia.
| | - Jennifer Philip
- Parkville Integrated Palliative Care Service (A.K.W., J.P., R.E., J.C., B.L.) Peter MacCallum Cancer Centre & The Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Medicine (A.K.W., J.P., O.W.), University of Melbourne, Fitzroy, Victoria, Australia
| | - Olivia Wawryk
- Department of Medicine (A.K.W., J.P., O.W.), University of Melbourne, Fitzroy, Victoria, Australia
| | | | - Jaclyn Yoong
- Northern Health (M.G.S., J.Y.), Victoria, Australia
| | - Rachel Everitt
- Parkville Integrated Palliative Care Service (A.K.W., J.P., R.E., J.C., B.L.) Peter MacCallum Cancer Centre & The Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Ruwani Mendis
- Western Health (R.M.), St Albans, Victoria, Australia
| | - Joyce Chua
- Parkville Integrated Palliative Care Service (A.K.W., J.P., R.E., J.C., B.L.) Peter MacCallum Cancer Centre & The Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Maria Pisasale
- Werribee Mercy Hospital (M.P.), Werribee, Victoria, Australia
| | - Brian Le
- Parkville Integrated Palliative Care Service (A.K.W., J.P., R.E., J.C., B.L.) Peter MacCallum Cancer Centre & The Royal Melbourne Hospital, Parkville, Victoria, Australia
| |
Collapse
|
6
|
Hall SAL, Vogrin S, Wawryk O, Burns GS, Visvanathan K, Sundararajan V, Thompson A. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut 2022; 71:1629-1641. [PMID: 34493592 DOI: 10.1136/gutjnl-2020-323979] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Accepted: 08/25/2021] [Indexed: 12/16/2022]
Abstract
BACKGROUND AND AIMS Sustained virological suppression and hepatitis B surface antigen (HBsAg) loss have been described after nucleot(s)ide analogue (NA) discontinuation for patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). We performed a meta-analysis of the clinical outcomes after NA discontinuation for HBeAg-negative CHB. METHODS Studies involving NA cessation in HBeAg-negative CHB individuals with a median follow-up of ≥12 months were included. Participants were HBeAg-negative at the time of NA initiation. Random effects meta-analyses were performed for the following clinical outcomes: (1) virological relapse (VR) at 6 and 12 months; (2) clinical relapse (CR) at 6 and 12 months and (3) HBsAg loss. Effect of other variables was estimated using subgroup analysis and meta-regression. Studies including patients stopping entecavir (ETV) and/or tenofovir disoproxil fumarate (TDF) were considered separately to studies including patients stopping older generation NA. RESULTS N=37 studies met inclusion criteria. Cumulative incidence of VR and CR after stopping ETV/TDF was 44% and 17% at 6 months and 63% and 35% at 12 months. Similar relapse rates were observed after stopping older NAs. Among patients stopping ETV/TDF, TDF cessation was associated with increased CR rates at 6 months versus ETV. There was an association between follow-up ≥4 years and HBsAg loss rates when stopping older NAs. Hepatic decompensation and hepatocellular carcinoma were rare but occurred more frequently in studies including cirrhotic individuals. CONCLUSION VR is common after NA discontinuation, however, CR was only seen in one-third of patients at 12 months. Stopping NA therapy can be followed by HBsAg clearance, and rates are higher with longer follow-up.
Collapse
Affiliation(s)
| | - Sara Vogrin
- Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia
| | - Olivia Wawryk
- Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia
| | - Gareth S Burns
- Gastroenterology Department, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Victoria, Australia
| | - Kumar Visvanathan
- Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.,Infectious Diseases Department, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Victoria, Australia
| | - Vijaya Sundararajan
- Department of Public Health, La Trobe University, Melbourne, Victoria, Australia
| | - Alexander Thompson
- Gastroenterology Department, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Victoria, Australia.,Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
7
|
Pasanen L, Le Gautier R, Wong A, Wawryk O, Collins A, Schwetlik S, Philip J. Telehealth in outpatient delivery of palliative care: A qualitative study of patient and physician views. Palliat Support Care 2022; 21:1-8. [PMID: 35818898 DOI: 10.1017/s1478951522000670] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVES The COVID-19 pandemic has widened the funded use of telehealth in Australia to support telehealth delivery to all patients in any setting. Increasing the use and experience of telehealth brings to light unique insights into the advantages and challenges of this new model of healthcare delivery This study aimed to qualitatively explore the experiences of both palliative care physicians and patients setting, including their views on its future role in healthcare. METHODS This qualitative study was conducted across three metropolitan tertiary palliative care centers in Victoria, Australia between November 2020 and March 2021. Purposive sampling identified 23 participants (12 physicians and 11 patients). Semi-structured interviews focused on the last telehealth consultation, thoughts and impressions of telehealth, and the possibility of telehealth remaining in palliative care. A thematic approach was adopted to code and analyze the data. RESULTS Telehealth transformed the ways physicians and patients in this study perceived and engaged with outpatient palliative care across the entire continuum of care. Four key themes were identified: (1) access to care; (2) delivery of care; (3) engagement with care; and (4) the future. SIGNIFICANCE OF RESULTS This study provides novel data bringing together the perspective of patients and physicians, which confirms the utility of telehealth in palliative care. Its convenience enables more frequent review, enables reviews to occur in response to lower levels of concern, and adds toward enhancing the continuity of care across and between settings. Moving forward, support seemed strongest for a hybrid model of telehealth and face-to-face consultations guided by key parameters relating to the level of anticipated complexity.
Collapse
Affiliation(s)
- Leeanne Pasanen
- Parkville Integrated Palliative Care Service, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Roslyn Le Gautier
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, VIC, Australia
| | - Aaron Wong
- Parkville Integrated Palliative Care Service, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Royal Melbourne Hospital, Parkville, VIC, Australia
| | - Olivia Wawryk
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, VIC, Australia
| | - Anna Collins
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, VIC, Australia
| | - Stephanie Schwetlik
- North Adelaide Palliative Service, Modbury Hospital, Modbury, South Australia
| | - Jennifer Philip
- Parkville Integrated Palliative Care Service, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, VIC, Australia
- Royal Melbourne Hospital, Parkville, VIC, Australia
| |
Collapse
|
8
|
Everitt R, Wong AK, Wawryk O, Le B, Yoong J, Pisasale M, Mendis R, Philip J. A multi-centre study on patients dying from COVID-19: Communication Between Clinicians, Patients, and their Families. Intern Med J 2022; 52:2068-2075. [PMID: 35471707 PMCID: PMC9111806 DOI: 10.1111/imj.15788] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 03/25/2022] [Accepted: 04/20/2022] [Indexed: 11/28/2022]
Abstract
Background COVID−19 has led to challenges in providing effective and timely communication in healthcare. Services have been required to adapt and evolve as successful communication remains core to high quality patient‐centred care. Aim This study aims to describe the communication between admitted patients, their families and clinicians (medical, nursing, allied health) during end‐of‐life care. Methods This retrospective review included all patients (n = 230) who died directly due to COVID‐19 at five Melbourne hospitals between 1 January and 31 December 2020. Contacts and modality used (face to face, video, telephone) during the 8 days prior to death were recorded. Results Patients were predominantly elderly (median age 86 years) and from residential aged care facilities (62% (n = 141)). Communication frequency increased the closer the patient was to death, where on day of death, contact between clinicians and patients was 93% (n = 213) clinicians and families 97%(n = 222) and between patients and families 50% (n = 115). Most contact between patients and families was facilitated by a clinician (91.3% (n = 105) day of death) with the most commonly used mode being video call (n = 30 day of death). Conclusion This study is one of the first and largest Australian reports on how communication occurs at the end of life for patients dying of COVID‐19. Contact rates were relatively low between patients and families, compared to other cohorts dying from non COVID‐19 related causes. The impact of this difference on bereavement outcomes requires surveillance and attention. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Rachel Everitt
- Palliative Medicine Registrar, The Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria, Australia, 3050
| | - Aaron K Wong
- The Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria, Australia, 3050.,Peter MacCallum Cancer Centre, 305, Grattan St, Parkville, Victoria, Australia, 3000.,Department of Medicine, University of Melbourne, Eastern Hill Campus, Victoria Parade, Fitzroy, Victoria, Australia, 3065
| | - Olivia Wawryk
- Department of General Practice, University of Melbourne, Parkville, Victoria, Australia, 3050
| | - Brian Le
- Parkville Integrated Palliative Care Service, The Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria, Australia, 3050.,Department of Medicine RMH, The University of Melbourne, Parkville, Victoria, Australia, 3050
| | - Jaclyn Yoong
- Northern Health, 185 Cooper Street, Epping, Victoria, Australia, 3076.,Monash Health, Monash University, 246 Clayton Road, Clayton, Victoria, Australia, 3168
| | - Maria Pisasale
- Werribee Mercy Hospital, 300-310 Princes Highway, Werribee, Victoria, Australia, 3030
| | - Ruwani Mendis
- Western Health, 176 Furlong Road, St Albans, Victoria, Australia, 3021.,Department of Medicine, Western Health, University of Melbourne, 176 Furlong Road, St Albans, Victoria, Australia, 3021
| | - Jennifer Philip
- Department of Medicine, University of Melbourne, Eastern Hill Campus, Victoria Parade, Fitzroy, Victoria, Australia, 3065.,St Vincent's Hospital, Palliative Care Service, Victoria Parade, Fitzroy, Victoria, Australia, 3065.,The Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria, Australia, 3050
| |
Collapse
|
9
|
Collins A, McLachlan SA, Pasanen L, Wawryk O, Philip J. Perceptions of telehealth in real-world oncological care: An exploration of matched patient- and clinician-reported acceptability data from an Australian cancer centre. Cancer Med 2022; 11:3342-3351. [PMID: 35373512 PMCID: PMC9468437 DOI: 10.1002/cam4.4700] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Revised: 02/04/2022] [Accepted: 02/20/2022] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND Prior to 2020, the use of telehealth in cancer care was limited, but COVID-19 necessitated its rapid and widespread adoption into routine care delivery. This study aimed to evaluate perceptions of telehealth through a dyadic exploration of matched cancer patient- and clinician-reported acceptability data and to explore factors that may predict greater suitability for telehealth. METHODS A prospective, cross-sectional, exploratory survey study assessed (matched) patient- and clinician-reported perceptions of telehealth consultations occurring at a metropolitan, tertiary-based cancer centre in Victoria, Australia. RESULTS One-hundred and fifty-five matched patient- and clinician-reported data were included. High rates of acceptability with telehealth were reported by patients (93%) and clinicians (91%), who mostly shared concordant views (86%). Factors significantly associated with increased acceptability for telehealth, included, for clinicians, greater familiarity with the patient (OR 8.20, 95% CI: 1.50-45.06, p = 0.02), and younger patient age (OR 1.06, 95% CI: 0.99-1.13, p = 0.05), and for patients was earlier stage disease (≤stage III) (OR 5.29, 95% CI: 1.08-25.82, p = 0.04). Lower acceptability for telehealth according to clinicians was associated with poorer patient performance status (OR 0.04, 95% CI 1.00-1.08, p = 0.04) and for patients with the need for an interpreter (0R 0.06, 95% CI: 0.008-0.51, p = 0.009). CONCLUSION While overall telehealth is acceptable in cancer care, our findings raise important implications for future service development, notably that it may be less optimal for patients with higher complexity of need-including those with more advanced disease, poorer performance status, those less well known to treating clinicians and those identified to have additional language barriers.
Collapse
Affiliation(s)
- Anna Collins
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Victoria, Australia
| | - Sue-Anne McLachlan
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Victoria, Australia.,Medical Oncology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
| | - Leeanne Pasanen
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Victoria, Australia
| | - Olivia Wawryk
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Victoria, Australia
| | - Jennifer Philip
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Victoria, Australia.,Parkville Integrated Palliative Care Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| |
Collapse
|
10
|
Philip J, Wawryk O, Pasanen L, Wong A, Schwetlik S, Collins A. Telehealth in outpatient delivery of palliative care: a prospective survey evaluation by patients and clinicians. Intern Med J 2022; 52:1144-1153. [PMID: 35189018 PMCID: PMC9540442 DOI: 10.1111/imj.15721] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 02/11/2022] [Accepted: 02/16/2022] [Indexed: 11/30/2022]
Abstract
Background In Australia during the COVID‐19 pandemic new funding models were introduced to support telehealth consultations, resulting in their widescale adoption in palliative care service delivery. Clarity around the clinical circumstances and patient populations that might be most appropriate for telehealth models was required. Aims To evaluate patient and physician satisfaction, acceptability and utility of outpatient palliative care provision through telehealth. Methods This is a multi‐site prospective, cross‐sectional, observational study conducted during a time of significant public health restrictions. A survey was used to collect matched patient‐ and physician‐reported perceptions of palliative care telehealth consultations across three metropolitan hospitals in Victoria, Australia. Results There were 127 matched patient–physician data of telehealth consultations and a further 812 physician‐only assessments. Telehealth was generally acceptable and satisfactory, with patients providing greater positive scores than clinicians. Telehealth incorporating both audio and video were more acceptable and satisfactory, particularly with the presence of a carer, and during routine reviews. Physicians were less satisfied using telehealth when there was increasing symptom complexity across all domains (pain, psychological, and other symptoms). Conclusions Telehealth has high utility in palliative care practice. A future hybrid model of care comprising both face‐to‐face and telehealth consultations seems favoured by patients and physicians but must be accompanied by targeted support for specific patient groups to ensure equitable healthcare access. Further evaluation of telehealth during a time of fewer public health emergency measures and lower community anxiety is required to fully understand its ongoing role.
Collapse
Affiliation(s)
- Jennifer Philip
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne.,Parkville Integrated Palliative Care Service, Peter MacCallum Cancer Centre.,Royal Melbourne Hospital, Parkville
| | - Olivia Wawryk
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne
| | - Leeanne Pasanen
- Parkville Integrated Palliative Care Service, Peter MacCallum Cancer Centre
| | - Aaron Wong
- Parkville Integrated Palliative Care Service, Peter MacCallum Cancer Centre.,Royal Melbourne Hospital, Parkville
| | - Stephanie Schwetlik
- North Adelaide Palliative Service, Modbury Hospital, Modbury, South Australia
| | - Anna Collins
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne
| |
Collapse
|
11
|
Sagar P, Wawryk O, Vogrin S, Whitham E, Kiley M, Frasca J, Carne R, Seneviratne U, Cook MJ, Lawn N, Nikpour A, D'Souza WJ. Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes. Epilepsy Behav 2021; 119:107935. [PMID: 33930626 DOI: 10.1016/j.yebeh.2021.107935] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Revised: 03/09/2021] [Accepted: 03/11/2021] [Indexed: 11/16/2022]
Abstract
PURPOSE To explore the efficacy and tolerability of adjuvant perampanel (PER) and their associated risk factors in late add-on drug-resistant epilepsy. METHOD Retrospective multicenter 'real-world' observational study. Consecutively identified patients commenced on PER, with mixed epilepsy syndromes, from nine Australian epilepsy centers. Primary efficacy endpoints were at least 50% reduction in seizure frequency (responders), seizure freedom, and retention at 6 and 12 months, following a 3-month titration period. Tolerability endpoints were cessation of PER for any reason, cessation of PER due to treatment-emergent adverse events (TEAE), or cessation due to inefficacy. Outcomes were assessed for a-priori risk factors associated with efficacy and tolerability. RESULTS Three-hundred and eighty seven adults were identified and followed up for a median of 12.1 months (IQR 7.0-25.2). Focal epilepsy accounted for 79.6% (FE), idiopathic generalized epilepsy (IGE), 10.3% and developmental epileptic encephalopathy (DEE) 10.1%, of the cohort. All patients had drug-resistant epilepsy, 71.6% had never experienced six months of seizure freedom, and the mean number of antiepileptic medications (AEDs) prior to starting PER was six. At 12 months, with missing cases classified as treatment failure, retention was 40.0%, responder 21.7%, and seizure freedom 9.0%, whereas, using last outcome carried forward (LOCF), responder and seizure freedom rates were 41.3% and 14.7%, respectively. Older age of epilepsy onset was associated with a marginal increase in the likelihood of seizure freedom at 12-month maintenance (OR 1.04, 95% CI 1.02, 1.06). Male sex (adjusted OR [aOR] 2.06 95% CI 1.33, 3.19), lower number of prior AEDs (aOR 0.84, 95% CI 0.74, 0.96) and no previous seizure-free period of at least 6-month duration (aOR 2.04 95% CI 1.21, 3.47) were associated with retention. Perampanel combined with a GABA receptor AED was associated with a lower responder rate at 12 months but reduced cessation of PER. The most common TEAEs were neuropsychiatric (18.86%), followed by dizziness (13.70%), and sleepiness (5.68%). CONCLUSIONS Adjuvant PER treatment, even in late-add on drug-resistant epilepsy is an effective and well-tolerated treatment for drug-resistant epilepsy.
Collapse
Affiliation(s)
- Parveen Sagar
- Department of Medicine, St Vincent's Hospital Melbourne, The University of Melbourne, Australia.
| | - Olivia Wawryk
- Department of Medicine, St Vincent's Hospital Melbourne, The University of Melbourne, Australia
| | - Sara Vogrin
- Department of Medicine, St Vincent's Hospital Melbourne, The University of Melbourne, Australia
| | - Emma Whitham
- Department of Neurology, Flinders Medical Centre, Australia
| | - Michelle Kiley
- Department of Neurology, Royal Adelaide Hospital, Australia
| | - Joseph Frasca
- Department of Neurology, Flinders Medical Centre, Australia
| | - Ross Carne
- Department of Medicine, St Vincent's Hospital Melbourne, The University of Melbourne, Australia
| | - Udaya Seneviratne
- Department of Medicine, St Vincent's Hospital Melbourne, The University of Melbourne, Australia; Department of Neurology, Monash Medical Centre, Melbourne, Australia
| | - Mark J Cook
- Department of Medicine, St Vincent's Hospital Melbourne, The University of Melbourne, Australia
| | - Nicholas Lawn
- Western Australian Adult Epilepsy Service, Sir Charles Gairdner Hospital, Perth, Australia
| | - Armin Nikpour
- Department of Neurosciences, Royal Prince Alfred Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Australia
| | - Wendyl Jude D'Souza
- Department of Medicine, St Vincent's Hospital Melbourne, The University of Melbourne, Australia
| |
Collapse
|
12
|
Russell B, Philip J, Wawryk O, Vogrin S, Burchell J, Collins A, Le B, Brand C, Hudson P, Sundararajan V. Validation of the responding to urgency of need in palliative care (RUN-PC) triage tool. Palliat Med 2021; 35:759-767. [PMID: 33478366 DOI: 10.1177/0269216320986730] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND The Responding to Urgency of Need in Palliative Care (RUN-PC) Triage Tool is a novel, evidence-based tool by which specialist palliative care services can manage waiting lists and workflow by prioritising access to care for those patients with the most pressing needs in an equitable, efficient and transparent manner. AIM This study aimed to establish the intra- and inter-rater reliability, and convergent validity of the RUN-PC Triage Tool and generate recommended response times. DESIGN An online survey of palliative care intake officers applying the RUN-PC Triage Tool to a series of 49 real clinical vignettes was assessed against a reference standard: a postal survey of expert palliative care clinicians ranking the same vignettes in order of urgency. SETTING/PARTICIPANTS Intake officers (n = 28) with a minimum of 2 years palliative care experience and expert clinicians (n = 32) with a minimum of 10 years palliative care experience were recruited from inpatient, hospital consultation and community palliative care services across metropolitan and regional Victoria, Australia. RESULTS The RUN-PC Triage Tool has good intra- and inter-rater reliability in inpatient, hospital consultation and community palliative care settings (Intraclass Correlation Coefficients ranged from 0.61 to 0.74), and moderate to good correlation to expert opinion used as a reference standard (Kendall's Tau rank correlation coefficients ranged from 0.68 to 0.83). CONCLUSION The RUN-PC Triage Tool appears to be a reliable and valid tool for the prioritisation of patients referred to specialist inpatient, hospital consultation and community palliative care services.
Collapse
Affiliation(s)
- Bethany Russell
- Palliative Nexus Research Group, University of Melbourne and St Vincent's Hospital Melbourne, VIC, Australia.,Department of Palliative Care, St Vincent's Hospital Melbourne, VIC, Australia
| | - Jennifer Philip
- Palliative Nexus Research Group, University of Melbourne and St Vincent's Hospital Melbourne, VIC, Australia.,Department of Palliative Care, St Vincent's Hospital Melbourne, VIC, Australia.,Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia.,Department of Palliative Care, The Royal Melbourne Hospital, Melbourne, VIC, Australia
| | - Olivia Wawryk
- Palliative Nexus Research Group, University of Melbourne and St Vincent's Hospital Melbourne, VIC, Australia.,Department of Public Health, La Trobe University, Melbourne, VIC, Australia
| | - Sara Vogrin
- Department of Medicine, St Vincent's Hospital Melbourne and University of Melbourne, Melbourne, VIC, Australia
| | - Jodie Burchell
- Department of Medicine, St Vincent's Hospital Melbourne and University of Melbourne, Melbourne, VIC, Australia
| | - Anna Collins
- Palliative Nexus Research Group, University of Melbourne and St Vincent's Hospital Melbourne, VIC, Australia
| | - Brian Le
- Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia.,Department of Palliative Care, The Royal Melbourne Hospital, Melbourne, VIC, Australia
| | - Caroline Brand
- Melbourne EpiCentre, University of Melbourne and Melbourne Health, Melbourne, VIC, Australia.,Department of Preventive Medicine, Monash University, Melbourne, VIC, Australia
| | - Peter Hudson
- Centre for Palliative Care, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.,End-of-life Care Research Group, Vrije University, Brussels, Belgium.,School of Health Sciences, University of Melbourne, Melbourne, VIC, Australia
| | - Vijaya Sundararajan
- Department of Public Health, La Trobe University, Melbourne, VIC, Australia.,Department of Medicine, St Vincent's Hospital Melbourne and University of Melbourne, Melbourne, VIC, Australia
| |
Collapse
|
13
|
Wong AK, Demediuk L, Tay JY, Wawryk O, Collins A, Everitt R, Philip J, Buising K, Le B. COVID-19 End-of-life Care: Symptoms and Supportive Therapy Use in an Australian Hospital. Intern Med J 2021; 51:1420-1425. [PMID: 33755283 PMCID: PMC8250873 DOI: 10.1111/imj.15300] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 03/15/2021] [Accepted: 03/17/2021] [Indexed: 11/28/2022]
Abstract
Background Descriptions of symptoms and medication use at end of life in COVID‐19 are limited to small cross‐sectional studies, with no Australian longitudinal data. Aims To describe end‐of‐life symptoms and care needs of people dying of COVID‐19. Methods This retrospective cohort study included consecutive admitted patients who died at a Victorian tertiary referral hospital from 1 January to 30 September directly due to COVID‐19. Clinical characteristics, symptoms and use of supportive therapies, including medications and non‐pharmacological interventions in the last 3 days of life were extracted. Results The cohort comprised 58 patients (median age 87 years, interquartile range (IQR) 81–90) predominantly admitted from home (n = 30), who died after a median of 11 days (IQR 6–28) in the acute medical (n = 31) or aged care (n = 27) wards of the hospital. The median Charlson Comorbidity Score was 7 (IQR 5–8). Breathlessness (n = 42), agitation (n = 36) and pain (n = 33) were the most frequent clinician‐reported symptoms in the final 3 days of life, with most requiring opioids (n = 52), midazolam (n = 40), with dose escalation commonly being required. While oxygen therapy was commonly used (n = 47), few (n = 13) required an anti‐secretory agent. Conclusions This study presents one of the first and largest Australian report of the end of life and symptom experience of people dying of COVID‐19. This information should help clinicians to anticipate palliative care needs of these patients, for example, recognising that higher starting doses of opioids and sedatives may help reduce prevalence and severity of breathlessness and agitation near death.
Collapse
Affiliation(s)
- Aaron K Wong
- Department of Palliative Care, The Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria, Australia, 3050
| | - Lucy Demediuk
- Palliative Medicine Registrar, The Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria, Australia, 3050
| | - Jia Yin Tay
- Palliative Medicine Registrar, The Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria, Australia, 3050
| | - Olivia Wawryk
- St Vincent's Hospital, Palliative Care Service, Victoria Parade, Fitzroy, Victoria, Australia, 3065
| | - Anna Collins
- St Vincent's Hospital, Palliative Care Service, Victoria Parade, Fitzroy, Victoria, Australia, 3065.,Department of Medicine, University of Melbourne, Eastern Hill Campus, Victoria Parade, Fitzroy, Victoria, Australia, 3065
| | - Rachel Everitt
- Palliative Medicine Registrar, The Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria, Australia, 3050
| | - Jennifer Philip
- Palliative Medicine Registrar, The Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria, Australia, 3050.,St Vincent's Hospital, Palliative Care Service, Victoria Parade, Fitzroy, Victoria, Australia, 3065.,Department of Medicine, University of Melbourne, Eastern Hill Campus, Victoria Parade, Fitzroy, Victoria, Australia, 3065
| | - Kirsty Buising
- The Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria, Australia, 3050
| | - Brian Le
- The Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria, Australia, 3050
| |
Collapse
|